Abstract library

6 results for "Zambrowicz".
#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome
Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jay L Mitchell
Authors:
#394 Efficacy of Telotristat Etiprate in Refractory Carcinoid Syndrome: Results of a Randomized, Placebo-controlled, Multicenter Study
Introduction: Diarrhea associated with carcinoid syndrome (CS) has been attributed to excess serotonin. Telotristat etiprate is an oral serotonin synthesis inhibitor that decreases peripheral serotonin production.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Matthew Kulke
Authors:
#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study
Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Marianne E Pavel
Authors:
#661 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Carcinoid Syndrome: Results of a Phase 2, Multicenter, Open-label, Serial-Ascending Study
Introduction: Excess serotonin (5-HT) in patients (pts) with carcinoid syndrome (CS) is associated with symptoms including increased bowel movement (BM) frequency.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
Authors:
#870 Telotristat Etiprate (TE) in a Cohort of Carcinoid Heart Disease Patients in Two Phase 2 Trials
Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). High levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) have also been linked with carcinoid heart disease (CaHD). Telotristat etiprate (TE), a novel, oral inhibitor of serotonin synthesis, is in Phase 3 development for the treatment of CS.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Darren Wheeler
Authors:
#1068 Telotristat Etiprate in a Subset of Carcinoid Syndrome Patients Who Have High Levels of Urinary 5-hydroxyindoleacetic Acid and Frequent Flushing
Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). CS patients (pts) with high levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) and >3 flushing episodes/day are at increased risk of developing carcinoid heart disease (CaHD).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: Darren Wheeler
Authors: